In Brief: Betaseron needle-free injection
Betaseron needle-free injection: Berlex parent Schering AG receives a review letter from FDA requiring "additional material clinical studies in order to use non-traditional delivery mechanisms with its Betaseron," jet injection device manufacturer Bioject states. Schering AG cancels its contract with Portland, Ore.-based Bioject. Berlex will begin offering a 24-hour nurse hotline in the first quarter to provide free injection training and follow-up support for Betaseron patients...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth